Form 4: Enliven Therapeutics COO Anish Patel Exercises Options and Sells Shares

Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, executed transactions involving the company's common stock on May 6, 2024.
• Patel exercised options to acquire 4,875 shares of common stock at a price of $2.48 per share.
• Simultaneously, Patel sold 4,875 shares of common stock at a weighted average price of $22.7219 per share, with individual sales ranging from $22.295 to $22.9429.
• Following these transactions, Patel directly owns no shares and indirectly owns 394,027 shares through The Patel / Dong Family Trust.
• The option exercise and subsequent sale were conducted under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• Patel also directly owns 55,842 employee stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider transactions are common, and the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on current inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a company officer, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates